Débora de Jesus Sena

Débora de Jesus Sena

Auto-generated profile, based on publicly available information

Débora de Jesus Sena

Center for Medical Sciences, Federal University of Paraíba, João Pessoa, Brazil

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2025 in Advances in Rheumatology
Verified
Journal Article
Open access
PDF file
MOMaria Nathalia Gabriela Rocha Pontes de Oliveira
Maria Nathalia Gabriela Rocha Pontes de Oliveira
DSDébora de Jesus Sena
Débora de Jesus Sena
AMAna Karla Guedes de Melo
Ana Karla Guedes de Melo
DEDanielle C. Soares Egypto
Danielle C. Soares Egypto
LBLuís Fábio Barbosa Botelho
Luís Fábio Barbosa Botelho
ABAlessandra de Sousa Braz
Alessandra de Sousa Braz
Background: In rheumatoid arthritis (RA), the persistence of pain despite adequate inflammatory control may indicate the involvement of nociplastic and/or neuropathic pain (NP). Objective: To investigate the presence of central sensitization (CS) and/or NP in patients with RA. Methods: This descriptive, cross-sectional study used convenience sampling and included adult patients (≥ 18 years) with RA diagnosed according to the 2010 classification criteria of the American College of Rheumatology – ACR. The following instruments were applied: Central Sensitization Inventory (CSI), PainDETECT Questionnaire (PD-Q), and the 2010/2011 ACR criteria for fibromyalgia (FM), revised in 2016 (the latter applied only to patients with CSI ≥ 40). Descriptive and predictive analyses were conducted with a significance level of 5%. Results: A total of 113 patients were included (mean age 54.3 years; 93.81% female; mean disease duration 12.11 years). CS was identified in 59.29% of patients; among them, 47.76% met FM criteria, while 52.24% did not. Among patients with CS, 53.73% reported severe pain (Numeric Rating Scale, NRS), and 44.78% had high disease activity (Clinical Disease Activity Index, CDAI). CSI was a significant predictor of both NRS and CDAI in univariate ( p < 0.001) and multivariate analyses ( p = 0.037 and p = 0.009, respectively). According to PD-Q, 17.70% of patients had probable NP, and PD-Q scores were predictive of CDAI, NRS, and CSI ( p < 0.001). Among patients with CS, 26.87% also showed overlapping NP. Conclusions: A substantial proportion of RA patients presented with CS-related pain, even in the absence of FM, suggesting a mixed (“top-down and bottom-up”) nociplastic pain profile. Both CS and NP were associated with higher pain levels and increased disease activity. This is the first Brazilian study to characterize the coexistence of CS-related pain (with or without FM) and NP in RA, offering relevant insights for the clinical management of chronic pain in this population. These findings reinforce that routine screening and assessment of CS and NP should be an integral and continuous component of RA management, preceding therapeutic adjustments and extending throughout follow-up.

24 September 2025 in Advances in Rheumatology
Verified
Journal Article
Open access
PDF file
DSDébora de Jesus Sena
Débora de Jesus Sena
MOMaria Nathalia Gabriela Rocha Ponte Oliveira
Maria Nathalia Gabriela Rocha Ponte Oliveira
MSMaria Roberta Melo Pereira Soares
Maria Roberta Melo Pereira Soares
LBLuís Fábio Barbosa Botelho
Luís Fábio Barbosa Botelho
ABAlessandra de Sousa Braz
Alessandra de Sousa Braz
Background: Chronic pain (CP) in radiographic Axial Spondyloarthritis (r-axSpA) is primarily peripheral nociceptive pain. However, many patients experience persistent pain despite treatment, suggesting other underlying mechanisms, such as central sensitization (CS) and neuropathy. This study assessed the presence of CS and/or neuropathic pain (NP) in r-axSpA patients treated at a University Hospital in the state of Paraiba. Methods: This quantitative, descriptive, and cross-sectional observational study used a convenience sample collected over 24 weeks. Instruments included the Central Sensitization Inventory - CSI (positive score ≥ 40); The PainDETECT Questionnaire - PD-Q (positive score ≥ 19); clinical epidemiological questionnaires, and preliminary diagnostic for fibromyalgia (FM) [American College of Rheumatology criteria of 2010/2011, revised in 2016], applied when CS positive. Inclusion criteria: patients diagnosed with r-axSpA; aged ≥ 18. Analyses performed: Descriptive; univariate and multivariate linear regressions; Student’s T-test. Results: This study included 52 patients (34 men and 18 women), of whom 61.54% had CS. Among these, 65.62% had FM, with an average widespread pain index of 7.87. NP was present in 17.31%, and 15.38% had both CS and NP. The CSI showed a positive correlation with Bath Ankylosing Spondylitis Disease Activity Index - BASDAI ( r = 0.574) and Axial Spondyloarthritis Disease Activity Score - ASDAS ( r = 0.622), while the PD-Q was positively correlated with BASDAI ( r = 0.515) and ASDAS ( r = 0.551). In the univariate analysis, CSI was a predictor ( p < 0.001) of both BASDAI and ASDAS, with 40.63% of patients scoring BASDAI ≥ 4 and 43.75% scoring ASDAS ≥ 2.1. Additionally, 66.67% of patients with PD-Q ≥ 19 had BASDAI ≥ 4 and 55.56% had ASDAS ≥ 2.1. The PD-Q was a predictor of BASDAI and ASDAS ( p < 0.001). Conclusions: This study is the first in the Brazilian scientific literature to investigate and demonstrate the occurrence of CS and/or NP in patients with r-axSpA, even when adequately treated. Another finding considered relevant was the demonstration of the presence of CS in 34.38% of patients who did not meet preliminary criteria for the diagnosis of FM, emphasizing the importance of investigating other painful mechanisms in chronic inflammatory joint diseases. These findings represent a first step for future research, in larger samples and in other forms of axial spondyloarthritis.